Description of Lapanix
Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase domains of both EGFR (ErbB1) and of HER2 (ErbB2) receptors. Lapatinib retained significant activity against HER2-amplified breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro and was synergistic in combination with trastuzumab in these cell lines.
|Generic||Brand Name||Formulation & Strength||Pack Size|
|Lapatinib||Lapanix||Tablet ( 250 mg )||150's Pot|
Website Prescribing Information Order Now